Literature DB >> 21051901

Epidemiology and seroprevalence of human immunodeficiency virus type 2.

Bineeta Kashyap1, Hitender Gautam, Preena Bhalla.   

Abstract

HIV-2 infection is detected sporadically mostly from the southern states of India. We did a retrospective analysis to find the seroprevalence of HIV-2 in and around Delhi. The study included all attendees of an integrated counseling and testing center (ICTC) from January 2004 to January 2009. As per NACO guidelines, samples showing positive results in three rapid tests were declared HIV-positive. Samples that were reactive for HIV-2 were further confirmed by Western blot assay. 8.8% (n = 1,938) of the clients were reactive for HIV-1, 0.03% (n = 6) were reactive for HIV-2 and 0.005% (n = 1) had HIV-1 and HIV-2 coinfection. Spouses of only 2 cases were tested, both resulting as nonreactive. History of travel or past stay to endemic states was present in 57% cases. The commonest risk factor revealed in them was sexual contact with commercial sex workers (86%). As such, seroprevalence of HIV-2 is very low but continued surveillance is needed for HIV-2 to understand the epidemiology and natural history of this complex human pathogen.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051901     DOI: 10.1159/000319929

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  3 in total

1.  HIV 2: A Benign Onlooker or A Subtle Threat?

Authors:  Ekadashi Rajni Sabharwal; Shweta Gupta; Gaurav Dalela
Journal:  J Clin Diagn Res       Date:  2014-05-15

2.  Seroprevalence of HIV-2 and dual infection among HIV-infected individuals with clinical and laboratory features at a Tertiary Care Teaching Hospital, Mangalore: The present scenario.

Authors:  Jutang Babat Ain Tiewsoh; Beena Antony; Rekha Boloor
Journal:  Ann Afr Med       Date:  2019 Apr-Jun

3.  HIV-1/2 differentiation in a South African public laboratory.

Authors:  Rendani T Mafuyeka; Lynne M Webber; Piet Becker; Simnikiwe H Mayaphi
Journal:  South Afr J HIV Med       Date:  2021-03-12       Impact factor: 2.744

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.